Kieran O's most recent trade in CTS Corp. was a trade of 3,743 Common Stock done at an average price of $55.6 . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.58 per share. | 09 Feb 2026 | 3,743 | 403,750 (1%) | 0% | 55.6 | 208,036 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.58 per share. | 09 Feb 2026 | 3,237 | 407,493 (1%) | 0% | 55.6 | 179,912 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 1,600 | 9,469 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 1,527 | 1,526 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 10.08 per share. | 09 Feb 2026 | 584 | 8,885 | - | 10.1 | 5,889 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 73 | 0 | - | - | Restricted Stock Units | |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.78 per share. | 06 Feb 2026 | 3,680 | 410,730 (1%) | 0% | 55.8 | 205,270 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 805 | 1,609 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2026 | 805 | 8,167 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 8.15 per share. | 15 Jan 2026 | 298 | 7,869 | - | 8.1 | 2,428 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 27,000 | 27,000 | - | - | Stock Options (Right to Buy) | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 75 | 7,387 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 75 | 73 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 10 Nov 2025 | 25 | 7,362 | - | 7.6 | 191 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 1,489 | 2,979 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 1,489 | 140,541 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.42 per share. | 12 Aug 2025 | 476 | 140,065 | - | 0.4 | 198 | Common Stock |
| LCI Ind | Kieran O'Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 1,687 | 1,687 | - | - | Restricted Stock Unit | |
| LCI Ind | Kieran O'Sullivan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 1,413 | 0 | - | - | Restricted Stock Unit | |
| LCI Ind | Kieran O'Sullivan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.96 per share. | 15 May 2025 | 1,413 | 22,961 (0%) | 0% | 89.0 | 125,700 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2025 | 1,490 | 4,468 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2025 | 1,490 | 139,529 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 09 May 2025 | 239 | 139,290 | - | 0.4 | 86 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.35 per share. | 09 May 2025 | 238 | 139,052 | - | 0.4 | 84 | Common Stock |
| Biodesix Inc | O’Kane Kieran | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 235,000 | 235,000 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | O’Kane Kieran | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 117,500 | 117,500 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 87,319 | 87,319 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 48,118 | 145,566 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 30,534 | 61,067 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.92 per share. | 10 Feb 2025 | 17,527 | 128,039 | - | 0.9 | 16,198 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 16,095 | 48,286 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 1,489 | 5,958 | - | - | Restricted Stock Units | |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.47 per share. | 08 Feb 2025 | 3,743 | 421,041 (1%) | 0% | 46.5 | 173,937 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.55 per share. | 08 Feb 2025 | 3,394 | 414,410 (1%) | 0% | 46.6 | 157,991 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.47 per share. | 08 Feb 2025 | 3,237 | 417,804 (1%) | 0% | 46.5 | 150,423 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 44,608 | 420,251 (1%) | 0% | 0 | Common Stock | |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 24,381 | 424,784 (1%) | 0% | 0 | Common Stock | |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.58 per share. | 06 Feb 2025 | 19,848 | 400,403 (1%) | 0% | 47.6 | 944,368 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 54.50 per share. | 06 Dec 2024 | 8,494 | 382,333 (1%) | 0% | 54.5 | 462,903 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.83 per share. | 06 Dec 2024 | 6,690 | 375,643 (1%) | 0% | 55.8 | 373,483 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.50 per share. | 04 Dec 2024 | 12,794 | 400,456 (1%) | 0% | 55.5 | 710,030 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 54.60 per share. | 04 Dec 2024 | 9,629 | 390,827 (1%) | 0% | 54.6 | 525,768 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.81 per share. | 02 Dec 2024 | 31,978 | 423,665 (1%) | 0% | 55.8 | 1,784,852 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.57 per share. | 02 Dec 2024 | 10,415 | 413,250 (1%) | 0% | 55.6 | 578,799 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 1,490 | 97,910 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 1,490 | 7,447 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 08 Nov 2024 | 238 | 97,672 | - | 1.4 | 331 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 08 Nov 2024 | 224 | 97,448 | - | 1.4 | 314 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 1,489 | 8,937 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 1,489 | 90,093 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.60 per share. | 08 Aug 2024 | 345 | 89,748 | - | 1.6 | 552 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.58 per share. | 08 Aug 2024 | 120 | 89,628 | - | 1.6 | 189 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 13,080 | 88,604 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 327 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | |
| LCI Ind | Kieran O'Sullivan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 110.83 per share. | 16 May 2024 | 1,357 | 21,548 (0%) | 0% | 110.8 | 150,396 | Common Stock |
| LCI Ind | Kieran O'Sullivan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2024 | 1,357 | 0 | - | - | Restricted Stock Unit | |
| LCI Ind | Kieran O'Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,354 | 1,354 | - | - | Restricted Stock Unit | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 1,489 | 75,992 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 1,489 | 10,426 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.48 per share. | 08 May 2024 | 468 | 75,524 | - | 1.5 | 692 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.11 per share. | 29 Apr 2024 | 27,905 | 455,643 (1%) | 0% | 47.1 | 1,314,630 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.02 per share. | 29 Apr 2024 | 9,771 | 483,548 (1%) | 0% | 47.0 | 459,396 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.00 per share. | 29 Apr 2024 | 6,179 | 493,319 (1%) | 0% | 47 | 290,413 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.00 per share. | 11 Apr 2024 | 2,064 | 499,498 (1%) | 0% | 47 | 97,008 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 327 | 327 | - | - | Series A Non-Voting Convertible Preferred Stock | |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.00 per share. | 01 Apr 2024 | 75 | 501,562 (1%) | 0% | 47 | 3,525 | Common Stock |
| CTS Corp | Kieran M. O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.13 per share. | 28 Mar 2024 | 14,976 | 501,637 (1%) | 0% | 47.1 | 705,778 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 35,307 | 35,307 | - | - | Stock Options (Right to buy) | |
| CTS Corp | O'Sullivan Kieran | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.74 per share. | 09 Feb 2024 | 3,394 | 519,872 (1%) | 0% | 45.7 | 155,242 | Common Stock |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.74 per share. | 09 Feb 2024 | 3,259 | 516,613 (1%) | 0% | 45.7 | 149,067 | Common Stock |
| CTS Corp | O'Sullivan Kieran | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.74 per share. | 09 Feb 2024 | 3,237 | 523,266 (1%) | 0% | 45.7 | 148,060 | Common Stock |
| Biodesix Inc | O’Kane Kieran | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 128,761 | 128,761 | - | - | Stock Options (Right to buy) | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 64,381 | 64,381 | - | - | Restricted Stock Units | |
| CTS Corp | O'Sullivan Kieran | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 63,547 | 529,397 (1%) | 0% | 0 | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 32,024 | 79,736 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 30,534 | 91,601 | - | - | Restricted Stock Units | |
| CTS Corp | O'Sullivan Kieran | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.19 per share. | 08 Feb 2024 | 28,238 | 501,159 (1%) | 0% | 44.2 | 1,247,837 | Common Stock |
| CTS Corp | O'Sullivan Kieran | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 25,344 | 526,503 (1%) | 0% | 0 | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.92 per share. | 08 Feb 2024 | 6,319 | 73,417 | - | 1.9 | 12,111 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.66 per share. | 08 Feb 2024 | 5,412 | 68,005 | - | 1.7 | 9,009 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,490 | 11,915 | - | - | Restricted Stock Units | |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.02 per share. | 06 Feb 2024 | 4,030 | 465,850 (1%) | 0% | 47.0 | 189,506 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 5,462 | 48,391 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 3,972 | 0 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 1,490 | 14,894 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 08 Aug 2023 | 850 | 47,541 | - | 1.4 | 1,180 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.27 per share. | 08 Aug 2023 | 849 | 46,692 | - | 1.3 | 1,076 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 1.62 per share. | 03 Aug 2023 | 6,172 | 42,929 | - | 1.6 | 9,999 | Common Stock |
| LCI Ind | Kieran O'Sullivan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 1,479 | 0 | - | - | Restricted Stock Unit | |
| LCI Ind | Kieran O'Sullivan | Director | Grant, award, or other acquisition of securities at price $ 114.53 per share. | 18 May 2023 | 1,479 | 20,191 (0%) | 0% | 114.5 | 169,390 | Common Stock |
| LCI Ind | Kieran O'Sullivan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,310 | 1,310 | - | - | Restricted Stock Unit | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 5,461 | 38,454 | - | - | Common Stock | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 3,972 | 3,972 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 1,489 | 16,384 | - | - | Restricted Stock Units | |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.57 per share. | 08 May 2023 | 1,223 | 37,231 | - | 1.6 | 1,916 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.58 per share. | 08 May 2023 | 474 | 36,757 | - | 1.6 | 747 | Common Stock |
| Biodesix Inc | Kieran O’Kane | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 52,531 | 52,531 | - | - | Stock Options (Right to buy) | |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 62,786 | 482,429 (1%) | 0% | 0 | Common Stock | |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.80 per share. | 09 Feb 2023 | 27,814 | 454,615 (1%) | 0% | 43.8 | 1,218,253 | Common Stock |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 21,918 | 473,139 (1%) | 0% | 0 | Common Stock | |
| CTS Corp | Kieran O'Sullivan | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.66 per share. | 09 Feb 2023 | 3,394 | 451,221 (1%) | 0% | 45.7 | 154,970 | Common Stock |